B-CELL ANTIBODY DISCOVERY: MORE DIVERSITY, FUNCTIONAL LEADS—IN JUST 24 HOURS.
With Berkeley Lights’ technology and platforms, discover hundreds of functional leads in just one day. Surpass the limitations of other methods.
FASTER DISCOVERY
HYBRIDOMA, PHAGE AND EBV-BASED WORKFLOWS LAST UP TO 3 MONTHS. THE BEACON® PLASMA B CELL WORKFLOW DELIVERS FUNCTIONAL ANTIBODIES IN A SINGLE DAY.
Our plasma B cell workflow identifies only the most qualified antibody leads early in the discovery process, with just a few touchpoints, on a platform that you control.
RAPID WORKFLOW
THE PLASMA B CELL WORKFLOW INTEGRATES 6 STEPS OF A TYPICAL HYBRIDOMA WORKFLOW TO ACCELERATE ANTIBODY DISCOVERY FROM 12 WEEKS TO 1 DAY.
Plasma B cells typically survive for less than a single day. The Beacon workflow enables direct screening of harvested plasma B cells without time-consuming hybridoma generation and screening.
PLASMA B CELL SCREENING
OUR OPTOSELECT™ CHIPS CAN SCREEN THOUSANDS OF PLASMA B CELLS AT THE SAME TIME.
With our OptoSelect chips, you can select rare antibodies by performing high-throughput screening of plasma B cells. Watch how it happens in our videos.
ANTIBODY DISCOVERY ASSAYS
WITH AS LITTLE AS A SINGLE CELL, YOU CAN RUN ASSAYS TO PERFORM IN-DEPTH CHARACTERIZATION OF ANTIBODY FUNCTION.
With a NanoPen™ volume of only 250 picoliters, reactions are fast and precise. Using basic assay building blocks with beads and reporter cells, you can build multiplexed or serial assays to assess antigen-specific binding and function. Better upfront characterization reduces the expense of having to sequence and clone irrelevant, non-functional hits.
FUNCTIONAL ASSAY
LIGAND BLOCKING ASSAY
CROSS-SPECIES ASSAY
ANTIGEN SPECIFIC BEAD ASSAY
RESULTS
THE BEACON® PLATFORM PRODUCES A WEALTH OF FUNCTIONAL AND SEQUENCE DATA THAT’S INVALUABLE FOR DISCOVERY OF RARE ANTIBODIES.
With the Beacon plasma B cell workflow, everything you need to connect antibody function to gene sequence at the single-cell level is available. Increase your chances of finding rare functional antibodies (e.g., 0.01% of the plasma B cell repertoire).
